Patients with atopic dermatitis maintain improvements for up to 2 years with lebrikizumab
Click Here to Manage Email Alerts
Key takeaways:
- Among patients taking lebrikizumab every 4 weeks, 83% to 96% reported a 4 point or more improvement on the questionnaire.
- Among patients taking lebrikizumab every 2 weeks, 94% to 100% reported the same.
WASHINGTON — Patients with moderate to severe atopic dermatitis treated with lebrikizumab maintained improvements in patient-reported outcomes, according to a poster presented here.
In the study, findings of which were presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting, David Rosmarin, MD, of Indiana University School of Medicine, and colleagues evaluated the impact of lebrikizumab on AD signs and symptoms.
Patients from ADjoin, the long-term extension of the ADvocate 1, ADvocate 2 and ADhere trials, were instructed to complete the Patient Oriented Eczema Measure questionnaire every week through 104 weeks of continuous treatment. Each patient rated their disease improvement by answering seven POEM questions on a scale of zero to 28, with a higher score indicating poorer quality of life.
Results showed that among patients treated with lebrikizumab once every 4 weeks, 96% and 83% reported a 4-point or more improvement in POEM in the ADvocate 1 and 2 (n = 99) and ADhere studies (n = 29), respectively. Further, 33% and 39% of patients in the respective trials also achieved POEM 0 or 1.
Overall, the mean total POEM score was 5.3 and 5.8 among patients treated once every 4 weeks with lebrikizumab in ADvocate 1 and 2 and ADhere, respectively.
Among patients that took lebrikizumab once every 2 weeks, 100% and 94% reported similar improvement in the respective trials. Also, 20% and 17% also achieved POEM 0 or 1. The mean POEM score was 6 and 5.4 in ADvocate 1 and 2 (n = 82) and ADhere (n = 57), respectively.
The authors concluded that not only did lebrikizumab allow for the maintenance of POEM improvements, but also, those improvements were not dictated by dosing regimens.
Reference:
Collapse
Rosmarin D, et al. Poster 019. Presented at: AAAAI Annual Meeting; Feb. 23-26, 2023; Washington, D.C.
Read more about
Click Here to Manage Email Alerts